Literature DB >> 21928412

Oral squamous cell carcinoma and a clinically negative neck: the value of follow-up.

Bart M Wensing1, Matthias A W Merkx, Paul F M Krabbe, Henri A M Marres, Frank J A Van den Hoogen.   

Abstract

BACKGROUND: In squamous cell carcinoma of the oral cavity (SCCOC), regular follow-up comprises 5 years of prescheduled visits, irrespective of tumor stage/classification and/or treatment. We analyzed our standard treatment and follow-up protocol in patients with a preoperative clinically negative neck (cN0) in SCCOC.
METHODS: This is a retrospective chart analysis. Inventarization of treatment, occult metastatic spread, and follow-up were performed.
RESULTS: In all, 197 patients were included. The occult metastatic rate was 24%. Eighty-three percent of recurrent disease presented within 2 years. Fifty-three percent of the patients with recurrent disease visited their physician outside prescheduled control visits.
CONCLUSIONS: Ultrasound-guided fine-needle aspiration cytology currently is 1 of the most reliable staging techniques in cN0 SCCOC. Regular follow-up could perhaps be limited from 5 to 2 years of prescheduled follow-up visits.
Copyright © 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21928412     DOI: 10.1002/hed.21642

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  8 in total

1.  Posttreatment Imaging in Patients with Head and Neck Cancer without Clinical Evidence of Recurrence: Should Surveillance Imaging Extend Beyond 6 Months?

Authors:  A Gore; K Baugnon; J Beitler; N F Saba; M R Patel; X Wu; B J Boyce; A H Aiken
Journal:  AJNR Am J Neuroradiol       Date:  2020-06-18       Impact factor: 3.825

2.  Evaluation of a post-treatment follow-up program in patients with oral squamous cell carcinoma.

Authors:  Andre Peisker; Gregor Franziskus Raschke; Arndt Guentsch; Paul Luepke; Korosh Roshanghias; Stefan Schultze-Mosgau
Journal:  Clin Oral Investig       Date:  2016-02-29       Impact factor: 3.573

3.  Disparities in adherence to head and neck cancer follow-up guidelines.

Authors:  Haley K Perlow; Stephen J Ramey; Vincent Cassidy; Deukwoo Kwon; Benjamin Farnia; Elizabeth Nicolli; Michael A Samuels; Laura Freedman; Nagy Elsayyad; Raphael Yechieli; Stuart E Samuels
Journal:  Laryngoscope       Date:  2018-12-24       Impact factor: 3.325

4.  Elective management of cervical and parotid lymph nodes in stage N0 cutaneous squamous cell carcinoma of the head and neck: a decision analysis.

Authors:  Wai Keat Wong; Randall P Morton
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-12-14       Impact factor: 2.503

Review 5.  Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma.

Authors:  Antoine Digonnet; Marc Hamoir; Guy Andry; Missak Haigentz; Robert P Takes; Carl E Silver; Dana M Hartl; Primož Strojan; Alessandra Rinaldo; Remco de Bree; Andreas Dietz; Vincent Grégoire; Vinidh Paleri; Johannes A Langendijk; Vincent Vander Poorten; Michael L Hinni; Juan P Rodrigo; Carlos Suárez; William M Mendenhall; Jochen A Werner; Eric M Genden; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-13       Impact factor: 2.503

6.  Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring.

Authors:  Daniel M Beswick; William E Gooding; Jonas T Johnson; Barton F Branstetter
Journal:  Laryngoscope       Date:  2012-06-08       Impact factor: 3.325

Review 7.  Post-therapeutic surveillance schedule for oral cancer: is there agreement?

Authors:  Guicai Liu; Eric J Dierks; R Bryan Bell; Tuan G Bui; Bryce E Potter
Journal:  Oral Maxillofac Surg       Date:  2012-09-02

8.  Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).

Authors:  Synnøve Magnussen; Oddveig G Rikardsen; Elin Hadler-Olsen; Lars Uhlin-Hansen; Sonja E Steigen; Gunbjørg Svineng
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.